BioSpace News Archive

Following Innova Medical Group’s parent company Pasaca Capital Inc.'s termination of Robert Kasprzak’s services as an employee, officer and director of Pasaca Capital Inc. and its subsidiaries, Robert Kasprzak ceased to be a director and the Chief Executive Officer of Innova Medical Group Inc. from Sept. 30, 2022.

Global molecular diagnostics innovator Sense Biodetection announced it has entered into a strategic agreement with Abacus dx for the non-exclusive distribution in Australia and New Zealand of Sense’s Veros instrument-free, point-of-care molecular testing platform.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Transcenta Holding Limited announces that TST004, its best-in-class, humanized monoclonal antibody targeting MASP2, has received IND clearance from U.S. Food and Drug Administration.

Ascletis Pharma Inc. announces dosing of the first patient in the 52-week Phase II clinical trial of thyroid hormone receptor β agonist ASC41 for treatment of liver biopsy-proven non-alcoholic steatohepatitis patients.